加拿大安大略省COVID-19大流行期间惰性淋巴瘤的诊疗实施与结局
该回顾性人群研究利用加拿大安大略省行政数据库,比较COVID-19大流行期间与大流行前惰性B细胞淋巴瘤患者的治疗模式与结局。共纳入4143例患者(大流行期1079例,大流行前3064例),中位年龄69岁。两时期均以苯达莫司汀联合利妥昔单抗(BR)为最常用方案,大流行期接受利妥昔单抗维持治疗或完成全程2年治疗的患者较少,医疗资源利用和感染并发症较少,死亡无差异。
要点
- 大流行期与大流行前均以BR为最常用方案,但大流行期利妥昔单抗维持治疗或完成2年全程治疗者较少(aHR 0.81,95%CI 0.71-0.92,p=0.001)。
- 大流行期急诊就诊(aHR 0.77,95%CI 0.68-0.88,p<0.0001)和住院(aHR 0.81,95%CI 0.70-0.94,p=0.0067)较少。
- 大流行期感染(aHR 0.69,95%CI 0.57-0.82,p<0.0001)和发热性中性粒细胞减少(aHR 0.66,95%CI 0.47-0.94,p=0.020)较少,死亡无差异。
核心结论
- 尽管一线方案使用相似,大流行期队列的医疗资源利用和感染相关住院较少,死亡无差异。
- 独立于疫苗接种,活跃的利妥昔单抗使用与较高的COVID-19并发症风险相关。
研究设计与样本
- 回顾性人群研究,使用加拿大安大略省行政数据库,随访至2022年3月31日。
- 共纳入4143例惰性B细胞淋巴瘤患者(大流行期1079例,大流行前3064例),中位年龄69岁。
- 主要结局为治疗模式;次要结局为死亡、毒性、医疗资源利用(急诊就诊、住院)和SARS-CoV-2结局。
- 采用Cox比例风险模型估计校正风险比(aHR)。
主要发现
- 两个时期均以苯达莫司汀联合利妥昔单抗(BR)为最常处方方案。
- 大流行期接受利妥昔单抗维持治疗或完成全程2年治疗的患者较少(aHR 0.81,95%CI 0.71-0.92,p=0.001)。
- 大流行期急诊就诊较少(aHR 0.77,95%CI 0.68-0.88,p<0.0001),住院较少(aHR 0.81,95%CI 0.70-0.94,p=0.0067)。
- 大流行期感染较少(aHR 0.69,95%CI 0.57-0.82,p<0.0001),发热性中性粒细胞减少较少(aHR 0.66,95%CI 0.47-0.94,p=0.020)。
- 死亡无差异;独立于疫苗接种,活跃的利妥昔单抗使用与较高的COVID-19并发症风险相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment pattern and outcomes in patients with indolent B-cell lymphoma treated during the coronavirus disease 2019 (COVID-19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population-based study using administrative databases in Ontario, Canada (follow-up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS-CoV-2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2-year course (aHR 0.81, 95% CI 0.71-0.92, p = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70-0.94, p = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57-0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47-0.94, p = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID-19 complications. Despite similar front-line regimen use, healthcare utilization and admissions for infection were less in the pandemic cohort.
引用
- Gong IY, Prica A, Ante Z, et al. Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada. Br J Haematol. 2023. PMID: 37886835. doi:10.1111/bjh.19166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。